Pharming Group reports first quarter 2025 financial results and provides business update

About this update from Pharming Group Nv

[{"type":"image","alt":"Pharming Group N.V.","displaySize":"","headline":null,"caption":"Pharming Group N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6VI_P53XoKPQr35Rp9bMIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 ","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE market","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"Joenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quarters","length":203,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating profit, adjusted to exclude the impact of non-recurring Abliva acquisition-related expenses, amounted to US$0.8 million compared to a US$16.3 million loss in the first quarter 2024","length":200,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched Joenja® (leniolisib) in England and Wales in April and preparing to file for U.S. FDA approval for pediatrics in the third quarter 2025","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed the acquisition of Abliva AB during the quarter and, in April, promptly started the second wave of recruitment for the pivotal FALCON clinical trial in mitochondrial DNA-driven primary mitochondrial diseases","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 total revenue guidance raised to US$325 - US$340 million, up from prior US$315 - US$335 million","length":110,"tagName":"p"}]},{"val":[{"type":"text","content":"Announces that Jeroen Wakkerman, Chief Financial Officer, will leave Pharming at the end of the month, to pursue other opportunities","length":132,"tagName":"p"}]},{"val":[{"...

More updates from Pharming Group Nv